Zura Bio Ltd

Zura Bio Ltd. (Nasdaq: ZURA) is a clinical-stage biopharmaceutical company that entered the public markets through a SPAC business combination and focuses on developing therapies for immune-mediated diseases, positioning itself within the biotechnology and immunology sector. The company completed its de-SPAC transaction in 2023 and has since operated as a reporting public company, as evidenced by its August 2026 Form 8-K filing with the Securities and Exchange Commission. Zura Bio's pipeline targets conditions driven by dysregulated immune responses, placing it among a growing cohort of SPAC-originated biotech names advancing clinical programs under public-market scrutiny. Sign up at SpacDesk for full deal history, filing alerts, and real-time ZURA data.